Get the Stockscreener App
29.05
7.92%
-2.50
Pre-market:
29.63
0.58
+2.00%
Faeth Therapeutics Inc stock is traded at $29.05, with a volume of 608.16K.
It is down -7.92% in the last 24 hours and down -16.31% over the past month.
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.
See More
Previous Close:
$31.55
Open:
$31.05
24h Volume:
608.16K
Relative Volume:
1.89
Market Cap:
$750.66M
Revenue:
-
Net Income/Loss:
$-184.46M
P/E Ratio:
-0.2035
EPS:
-142.7277
Net Cash Flow:
$-24.11M
1W Performance:
-17.31%
1M Performance:
-16.31%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$27.66
$31.05
1-Week Range:
$27.66
$35.57
52-Week Range:
$17.50
$42.14
Faeth Therapeutics Inc Stock (FTH) Company Profile
Name
Faeth Therapeutics Inc
Sector
Industry
Phone
(240) 243-8000
Address
1405 RESEARCH BLVD, SUITE 125, ROCKVILLE
Compare FTH vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FTH
Faeth Therapeutics Inc
|
29.05 | 750.66M | 0 | -184.46M | -24.11M | -142.73 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Faeth Therapeutics Inc Stock (FTH) Latest News
Faeth Therapeutics, Inc.(NasdaqCM:FTH) added to S&P Biotechnology Select Industry Index - marketscreener.com
Faeth Therapeutics: 'Buy' PIKTOR EC Data Year-End 2026 And HR+/HER2- BC Drug Expansion - Seeking Alpha
Faeth Therapeutics Adds Cancer Expert to Board - TipRanks
Faeth Therapeutics (FTH) Adds Renowned Cancer Biologist Dr. Kare - GuruFocus
Faeth Therapeutics appoints Karen Vousden to board - Investing.com
Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors - finance.yahoo.com
Faeth stock gets new Buy at Guggenheim (FTH:NASDAQ) - Seeking Alpha
Faeth Therapeutics at Morgan Stanley conference: oral cancer strategy By Investing.com - Investing.com Nigeria
FTH Initiated Coverage by Guggenheim -- Price Target Announced a - GuruFocus
Faeth Therapeutics Director Karen H. Vousden Granted 25,000 Stock Options - Kalkine Media
Faeth Therapeutics (FTH) awards 25,000 stock options to director - stocktitan.net
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
FTH Initiates Coverage On by Lucid Capital Markets -- Price Targ - GuruFocus
Faeth Therapeutics at Cantor Fitzgerald conference: oral PI3K push By Investing.com - Investing.com Canada
A booming business on Wall Street would love more biotechs to quietly die - BioPharma Dive
TD Cowen initiates Faeth Therapeutics stock with buy rating By Investing.com - Investing.com South Africa
symbol__ Stock Quote Price and Forecast - CNN
FTH Initiated Coverage by TD Cowen -- Rating Set to Buy - GuruFocus
Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026 - BioSpace
SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition - Stocktwits
Faeth Therapeutics stock hits 52-week high at 40.89 USD By Investing.com - Investing.com Australia
Faeth Therapeutics stock hits 52-week high at 40.89 USD - investing.com
Bullish Faeth Therapeutics Insiders Rewarded As Their Investment Rises To US$1.94m - simplywall.st
Insiders of Faeth Therapeutics Getting Good Value On Their US$1.19m Investment - Moomoo
Biotech Stocks At 52-Week HighsOABI +13%, FRNM, EXEL, FTH, LFST - RTTNews
What Makes Faeth Therapeutics, Inc. (FTH) a Strong Momentum Stock: Buy Now? - Eastern Progress
Faeth Therapeutics to Participate in Upcoming September Investor Conferences - Business Wire
Faeth Therapeutics (FTH) Grants Stock Options to New Hires Amid Unprofitable Growth Phase - GuruFocus
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - finance.yahoo.com
Capital expenditures of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Wall Street Analysts Predict a 72.22% Upside in Faeth Therapeutics, Inc. (FTH): Here's What You Should Know - finance.yahoo.com
FAETH THERAPEUTICS, INC : NEEDHAM INITIATES COVERAGE WITH BUY RATING; PRICE TARGET $56 - Bitget
Needham initiates Faeth Therapeutics stock with buy rating on cancer drug potential - Investing.com Canada
FTH Initiates Coverage On by Needham -- Buy Rating with $56 Pric - GuruFocus
Needham Initiates Faeth Therapeutics at Buy With $56 Price Target - finance.yahoo.com
Khosla Ventures Seed Associates D, Llc Net Worth (2026) - GuruFocus
Why is Faeth Therapeutics stock surging today? By Investing.com - Investing.com Canada
Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer - BioSpace
FDA grants fast track status to Faeth’s endometrial cancer drug - Investing.com
Faeth Therapeutics (FTH) Gains FDA Fast Track for Endometrial Ca - GuruFocus
FDA grants fast track status to Faeth’s endometrial cancer drug By Investing.com - Investing.com Canada
FTH: Faeth Therapeutics, Inc.Insider Transations - Zacks Investment Research
Faeth TherapeuticsFTHStock Price & News - The Motley Fool
Faeth Therapeutics (FTH) investor Caligan reports 2.4% stake in 13G/A - Stock Titan
Faeth Therapeutics (FTH) investor Trails Edge reports 2.0% beneficial stake in 13G/A - Stock Titan
Faeth Therapeutics (FTH): Khosla Ventures group discloses 10.2% ownership stake - Stock Titan
Faeth Therapeutics, Inc. (NASDAQ: FTH) Share Price, FTH Stock News, FTH Share Price & Updates - kalkine.ca
PR News | On the Move: Finn Names Flach PartnerFri., Aug. 14, 2026 - O'Dwyer's PR
Faeth Therapeutics (FTH) investor group reports 0% ownership in amended 13G - Stock Titan
Faeth Therapeutics Strengthens Executive Team With Senior Leadership Appointments - TradingView
Faeth Therapeutics Adds Senior Leaders Ahead of PIKTOR Clinical Milestones - citybiz
Faeth Therapeutics Inc Stock (FTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):